Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trial
Phase 1
- Conditions
- ObesityTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2022-501649-54-01
- Lead Sponsor
- Gentofte Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Age 18–75 years, BMI = 30 kg/m², History of at least one attempt to lose body weight
Exclusion Criteria
A self-reported change in body weight = 5% within the last 90 days prior to the screening visit, Treatment with any therapy, including endoscopic procedures and/or medication (e.g. liraglutide, bupropion/naltrexone and orlistat), intended for weight management within 90 days prior to screening, Previous, current, or planned (during the trial period) obesity treatment with surgery or a weight loss device < 1 year prior to screening, Glycated haemoglobin (HbA1c) = 48 mmol/mol, History of type 1 diabetes or type 2 diabetes
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method